The Path to Healing: Standard Treatment & Medications
At a Glance
Idiopathic scleritis treatment usually starts with oral anti-inflammatory medicine for milder disease and may progress to prednisone, immune-suppressing medicines, or biologics for severe or recurring inflammation. Doctors monitor eye findings, pain, medication risks, and steroid dose.
Because idiopathic scleritis is often presumed to be an immune-mediated condition, the goal of treatment is to “calm” the overactive immune response before it can damage the structure of the eye [1]. Doctors tailor treatment based on severity and response, often beginning with milder systemic treatments and moving to more powerful medications if the inflammation persists, returns, or is highly sight-threatening [2][3].
Step 1: Oral NSAIDs (For Mild to Moderate Disease)
For many patients with diffuse or nodular non-necrotizing scleritis, an initial line of defense is oral nonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin or naproxen [2][3].
- How they work: These medications block the enzymes that create the chemical signals for pain and swelling [2].
- What to expect: Unlike the drops used for simple “red eye,” these are systemic pills that work throughout the body. While they can be effective, they may take time to reach full effect. Your doctor will weigh the risks of gastrointestinal bleeding/ulcers, kidney damage, cardiovascular issues, and pregnancy considerations, and monitor you accordingly [3].
Step 2: Systemic Corticosteroids (For Rapid Control)
If NSAIDs are not enough, or if you present with a more aggressive form like rapidly progressive, posterior, or vision-threatening scleritis, your doctor will likely move to systemic corticosteroids (such as prednisone) [4][5].
- The Goal: Steroids are highly effective at quickly stopping active inflammation to prevent vision loss [4].
- The Taper and Safety: Never stop prednisone abruptly, as this can cause severe health complications. Steroids are generally not intended for long-term use at high doses due to side effects. Your doctor will slowly “taper” (lower) your dose as the eye improves [6]. Monitoring includes checking for infection risk, blood sugar changes, blood pressure changes, mood/sleep effects, and bone protection [7][3]. If the inflammation flares back up during this taper, it is a signal that a different approach is needed [6].
Step 3: Steroid-Sparing Agents (For Long-term Control)
If your scleritis is refractory (doesn’t respond to steroids) or recurrent (keeps coming back), or if you cannot tolerate the side effects of steroids, your doctor may introduce conventional immunomodulators [6][3]. These are often called “steroid-sparing” agents because they allow you to lower or stop your steroid dose while keeping the eye calm.
- Methotrexate: This is one of the most common options. In small observational cohorts, a large majority of patients achieved inflammation control within a year of starting methotrexate [6][7].
- Other Options: Your doctor might also consider medications like Mycophenolate Mofetil (CellCept) or Azathioprine [8]. These medications require several weeks or months to reach full effectiveness. They require strict compliance with regular blood tests to monitor your liver and blood counts, as well as counseling regarding infection risk and pregnancy [6][7].
Step 4: Biologics and Advanced Therapies
For the most severe cases—such as severe necrotizing disease, or cases that have failed conventional treatments—doctors may use biologics [9][5]. (Note: these are generally used off-label for scleritis).
- TNF Inhibitors: Medications like adalimumab or infliximab target specific proteins in the immune system [5][8].
- Rituximab: This biologic targets the B-cells of the immune system. In a small observational study of 15 patients with refractory scleritis, 14 showed clinical improvement after treatment with rituximab [9].
- Other Agents: For severe vasculitic necrotizing disease, agents like cyclophosphamide may be used under specialist care.
Monitoring Your Progress
Treatment success is not just about how well you can see. Your doctor will use clinical exams and imaging to measure:
- Redness and Inflammation: Is the deep-red or purple color fading? [9][10]
- Scleral Thickness: Using imaging like Ultrasound Biomicroscopy (UBM) or OCT, doctors can objectively measure if the swelling inside the eye wall is decreasing [11].
- Pain: A decrease in the deep, boring ache is often the first sign that a treatment is working [9].
- Steroid Load: A major goal is being able to control the disease using a minimal dose of steroids or none at all [6][7].
Important Note: Never start, stop, or taper these medicines without your prescriber’s instructions, and never self-treat with over-the-counter redness-relief drops. Before starting systemic treatments, your doctor will consider whether an infection is present, as using steroids or immunosuppressants on an infected eye can worsen the infection [12][4][13].
Common questions in this guide
What medicine is usually tried first for mild idiopathic scleritis?
When are prednisone or other steroids used for scleritis?
What are steroid-sparing medicines, and when might I need one?
Are biologic medicines used to treat severe scleritis?
How will my doctor know whether scleritis treatment is working?
What should I avoid while taking medicine for idiopathic scleritis?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my subtype (diffuse, nodular, etc.), is starting with an NSAID appropriate, or is my case severe enough to require corticosteroids immediately?
- 2.If we start with prednisone, what is the 'taper' schedule, and at what point would we consider moving to a steroid-sparing agent like methotrexate?
- 3.How will you monitor me for the side effects of these stronger medications, such as changes in my blood counts, liver function, or bone density?
- 4.What clinical signs are you using to determine if my treatment is working?
- 5.Are my vaccinations up to date, and are there any I should receive before we potentially start a biologic or immunosuppressant?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (13)
- 1
[Diagnostic and Therapeutic Management of Episcleritis and Scleritis].
Turgut F, Dingerkus V, Tappeiner C, Becker M
Klinische Monatsblatter fur Augenheilkunde 2023; (240(5)):725-738 doi:10.1055/a-2022-0689.
PMID: 36827997 - 2
Management of noninfectious scleritis.
Abdel-Aty A, Gupta A, Del Priore L, Kombo N
Therapeutic advances in ophthalmology 2022; (14()):25158414211070879 doi:10.1177/25158414211070879.
PMID: 35083421 - 3
Current Approach for the Diagnosis and Management of Noninfective Scleritis.
Dutta Majumder P, Agrawal R, McCluskey P, Biswas J
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; (10(2)):212-223 doi:10.1097/APO.0000000000000341.
PMID: 33290287 - 4
Nodular syphilitic scleritis masquerading as an ocular tumor.
Shaikh SI, Biswas J, Rishi P
Journal of ophthalmic inflammation and infection 2015; (5()):8 doi:10.1186/s12348-015-0040-5.
PMID: 25861399 - 5
Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review.
Sota J, Girolamo MM, Frediani B, et al.
Ophthalmology and therapy 2021; (10(4)):777-813 doi:10.1007/s40123-021-00393-8.
PMID: 34476773 - 6
Methotrexate for the treatment of noninfectious scleritis.
Sands DS, Chan SCY, Gottlieb CC
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2018; (53(4)):349-353 doi:10.1016/j.jcjo.2017.11.009.
PMID: 30119788 - 7
Clinical characteristics and efficacy of methotrexate in Japanese patients with noninfectious scleritis.
Hiyama T, Harada Y, Kiuchi Y
Japanese journal of ophthalmology 2021; (65(1)):97-106 doi:10.1007/s10384-020-00778-5.
PMID: 33107015 - 8
Scleritis associated with relapsing polychondritis.
Sainz-de-la-Maza M, Molina N, Gonzalez-Gonzalez LA, et al.
The British journal of ophthalmology 2016; (100(9)):1290-4 doi:10.1136/bjophthalmol-2015-306902.
PMID: 26888976 - 9
Rituximab in the Treatment of Refractory Noninfectious Scleritis.
Cao JH, Oray M, Cocho L, Foster CS
American journal of ophthalmology 2016; (164()):22-8.
PMID: 26766304 - 10
New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy.
Fabiani C, Sota J, Sainz-de-la-Maza M, et al.
Mediators of inflammation 2020; (2020()):8294560 doi:10.1155/2020/8294560.
PMID: 32410867 - 11
Morphometric Assessment of Sclera and Ciliary Body in Patients with Noninfectious Anterior Scleritis: A Quantitative Study Using Ultrasound Biomicroscopy.
Liu T, Ma G, Xu W, et al.
Ocular immunology and inflammation 2024; (32(9)):2000-2007 doi:10.1080/09273948.2024.2315189.
PMID: 38376887 - 12
Scleritis: Differentiating infectious from non-infectious entities.
Murthy SI, Sabhapandit S, Balamurugan S, et al.
Indian journal of ophthalmology 2020; (68(9)):1818-1828 doi:10.4103/ijo.IJO_2032_20.
PMID: 32823398 - 13
Occult Fungal Scleritis.
Jeang LJ, Davis A, Madow B, et al.
Ocular oncology and pathology 2017; (3(1)):41-44 doi:10.1159/000449103.
PMID: 28275602
This page is for informational purposes only and does not constitute medical advice. Your eye specialist should choose, monitor, and taper idiopathic scleritis treatment based on your specific situation.
Get notified when new evidence is published on Idiopathic scleritis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.